PRICENTRIC

PRICENTRIC™, a Global Pharmaceutical Pricing Portal delivering robust pricing intelligence, essential for optimizing pricing strategies worldwide

[PRICENTRIC @PricentricALSCG]

Balversa (erdafitinib) from Janssen pharmaceutical wins FDA approval for urothelial carcinoma #CANCER
https://t.co/8yPiC0BD1R

[PRICENTRIC @PricentricALSCG]

Roche's Tecentriq wins FDA approval for initial treatment of adults with extensive-stage small cell #lungcancer
https://t.co/VCv2YgNJmC

[PRICENTRIC @PricentricALSCG]

AstraZeneca's Saracatinib gets Orphan drug designation by FDA for idiopathic pulmonary fibrosis
https://t.co/5OkTVarX52

[PRICENTRIC @PricentricALSCG]

Roche’s MabThera gets European commission approval in pemphigus vulgaris #RareDisease
https://t.co/CpzZnrk5Wv

[PRICENTRIC @PricentricALSCG]

Dupixent (dupilumab) from Regeneron gets FDA's priority review for rhinosinusitis with nasal polyps.
https://t.co/5uRRTjZDYJ

[PRICENTRIC @PricentricALSCG]

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) https://t.co/6VnfvB4jMX

[PRICENTRIC @PricentricALSCG]

European Commission approves Roche’s Hemlibra for people with severe hemophilia A without factor VIII inhibitors https://t.co/qRLVzVk4lr

[PRICENTRIC @PricentricALSCG]

Rocklatan (netarsudil and latanoprost ophthalmic solution) receives FDA approval for open-angle glaucoma or ocular hypertension
https://t.co/luYuyxaQ4h

[PRICENTRIC @PricentricALSCG]

Dupixent (dupilumab) from Sanofi gets approval from FDA for dermatitis in adolescents
https://t.co/fyaJYH3L2V

[PRICENTRIC @PricentricALSCG]

Herceptin's biosimilar Trazimera receives FDA approval.
https://t.co/TWM4kNXPTM

[PRICENTRIC @PricentricALSCG]

U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin® https://t.co/pHWVBBMOJh

[PRICENTRIC @PricentricALSCG]

FDA APPROVES DUPIXENT® (DUPILUMAB) FOR MODERATE-TO-SEVERE ATOPIC DERMATITIS IN ADOLESCENTS https://t.co/mScG8IuRtM

[PRICENTRIC @PricentricALSCG]

Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine https://t.co/dKGBBX558P

[PRICENTRIC @PricentricALSCG]

Dupixent (dupilumab) of Sanofi gets approval from FDA for dermatitis in adolescents
https://t.co/fyaJYH3L2V

[PRICENTRIC @PricentricALSCG]

FDA grants Roche’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer https://t.co/bbFCJkx68Q

[PRICENTRIC @PricentricALSCG]

IMBRUVICA® (ibrutinib) Combination Regimen to Treat Waldenström's Macroglobulinemia Approved Through Health Canada Priority Review https://t.co/Bfvzeknx4s

[PRICENTRIC @PricentricALSCG]

European Commission approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer https://t.co/8PqdVZfDPv

[PRICENTRIC @PricentricALSCG]

CHMP recommends Keytruda for six-week dosing schedule in all existing monotherapy indications.
https://t.co/A53wCRONhN

[PRICENTRIC @PricentricALSCG]

Lilly Receives FDA Priority Review Designation for Emgality® (galcanezumab-gnlm) Injection for the Preventive Treatment of Episodic Cluster Headache in Adults https://t.co/SyGQIKYU4n

[PRICENTRIC @PricentricALSCG]

Eli Lilly to market generic version of Humalog at half price. #diabetes
https://t.co/arTImFfawF